Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:BFRGNASDAQ:CTORNASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.02-1.0%$1.06$0.86▼$3.60$61.78M0.09293,328 shs329,394 shsBFRGBullfrog AI$1.85$1.72$1.23▼$4.84$17.42M0.71392,457 shs70,650 shsCTORCitius Oncology$0.91$0.76$0.55▼$4.42$65.11M-0.171.09 million shs13,909 shsXCURExicure$10.04-4.5%$11.51$1.44▼$36.00$63.43M3.86572,388 shs4,221 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-0.97%-4.67%0.00%-26.88%-71.67%BFRGBullfrog AI0.00%+5.71%+5.11%-35.09%-39.34%CTORCitius Oncology0.00%-0.55%+35.82%-22.22%+90,999,900.00%XCURExicure-3.51%-0.20%-10.83%+17.43%+2,058.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.3511 of 5 stars3.73.00.00.01.51.70.6BFRGBullfrog AI0.4688 of 5 stars0.04.00.00.00.02.50.0CTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/AXCURExicure1.4482 of 5 stars0.05.00.04.70.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33618.95% UpsideBFRGBullfrog AI 0.00N/AN/AN/ACTORCitius Oncology 2.00Hold$3.00229.67% UpsideXCURExicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BFRG, ABOS, CTOR, and XCUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ABFRGBullfrog AI$60K290.30N/AN/A$0.43 per share4.30CTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/AXCURExicure$500K126.87N/AN/A$1.75 per share5.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%8/12/2025 (Estimated)BFRGBullfrog AI-$5.36M-$0.81N/A∞N/AN/A-141.39%-124.63%N/ACTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%N/AXCURExicure-$16.91M-$4.81N/A∞N/AN/A-190.90%-36.75%6/4/2025 (Estimated)Latest BFRG, ABOS, CTOR, and XCUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/A3/18/2025Q4 2024XCURExicureN/A-$3.39N/A-$3.39N/AN/A3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43BFRGBullfrog AIN/A5.905.90CTORCitius Oncology0.080.340.08XCURExicureN/A0.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%BFRGBullfrog AI0.96%CTORCitius Oncology70.52%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%BFRGBullfrog AI33.90%CTORCitius Oncology4.57%XCURExicure3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableCTORCitius OncologyN/A71.55 million55.17 millionN/AXCURExicure506.32 million2.50 millionNot OptionableBFRG, ABOS, CTOR, and XCUR HeadlinesRecent News About These CompaniesExicure, Inc. (NASDAQ:XCUR) Short Interest Down 19.8% in AprilMay 4, 2025 | marketbeat.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myelomaApril 16, 2025 | pharmabiz.comExicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100April 15, 2025 | pharmabiz.comExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comExicure, Inc. Reports Full Year 2024 Financial ResultsMarch 18, 2025 | gurufocus.comExicure secures Australian patent for cancer treatmentMarch 15, 2025 | investing.comExicure announces issuance of new patent in AustraliaMarch 15, 2025 | markets.businessinsider.comExicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in AustraliaMarch 13, 2025 | gurufocus.comKuehn Law Encourages Investors of Exicure, Inc. to Contact Law FirmJanuary 27, 2025 | markets.businessinsider.comExicure announces purchase agreement with GPCR TherapeuticsJanuary 24, 2025 | markets.businessinsider.comCORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 23, 2025 | businesswire.comExicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 22, 2025 | businesswire.comWhen the Price of (XCUR) Talks, People ListenJanuary 21, 2025 | news.stocktradersdaily.comWhen (XCUR) Moves Investors should ListenJanuary 11, 2025 | news.stocktradersdaily.com(XCUR) Technical Pivots with Risk ControlsJanuary 1, 2025 | news.stocktradersdaily.comExicure signs MOU with GPCR TherapeuticsDecember 27, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTurbulence for Joby Shares: What's Behind the Recent Dip?By Jeffrey Neal Johnson | May 22, 2025View Turbulence for Joby Shares: What's Behind the Recent Dip?These 3 Cybersecurity Stocks Are Defying the DownturnBy Ryan Hasson | April 29, 2025View These 3 Cybersecurity Stocks Are Defying the DownturnGoogle Is Betting Big on Nuclear Reactors—Should You?By Dan Schmidt | May 9, 2025View Google Is Betting Big on Nuclear Reactors—Should You?3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBy Nathan Reiff | May 16, 2025View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is LikelyBy Thomas Hughes | May 1, 2025View BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is LikelyBFRG, ABOS, CTOR, and XCUR Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.02 -0.01 (-0.97%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.01 -0.01 (-1.37%) As of 05/23/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Bullfrog AI NASDAQ:BFRG$1.85 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.89 +0.04 (+2.16%) As of 05/23/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Citius Oncology NASDAQ:CTOR$0.91 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.91 0.00 (0.00%) As of 05/23/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Exicure NASDAQ:XCUR$10.04 -0.47 (-4.47%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$10.06 +0.03 (+0.25%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
